Shirin Khakpour
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Shirin Khakpour has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
- Amir A. Farajian
Department of Mechanical and Materials Engineering, Wright State University, Dayton, OH 45435, USA
1 shared publication - Hamid Hosano
Biomaterials and Bioelectrics Department, Institute of Industrial Nanomaterials, Kumamoto University, Kumamoto 860-8555, Japan
1 shared publication - Nushin Hosano
Department of Biomaterials and Bioelectrics, Institute of Industrial Nanomaterials, Kumamoto University, Kumamoto 860-8555, Japan
1 shared publication - Zahra Moosavi-Nejad
Department of Biotechnology, Faculty of Biological Sciences, Alzahra University, Tehran 1993893973, Iran
1 shared publication
Latest Publications
- Open Access
- 1 July 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (7) , 887
Advancing Tumor Therapy: Development and Utilization of Protein-Based Nanoparticles
Protein-based nanoparticles (PNPs) in tumor therapy hold immense potential, combining targeted delivery, minimal toxicity, and customizable properties, thus paving the way for innovative approaches to cancer treatment. Understanding the various methods available for their production is crucial for researchers and scientists aiming to harness these nanoparticles for diverse applications, including tumor therapy, drug delivery, imaging, and tissue engineering. This review delves into the existing techniques for producing PNPs and PNP/drug complexes, while also exploring alternative novel approaches. The methods outlined in this study were divided into three key categories based on their shared procedural steps: solubility change, solvent substitution, and thin flow methods. This classification simplifies the understanding of the underlying mechanisms by offering a clear framework, providing several advantages over other categorizations. The review discusses the principles underlying each method, highlighting the factors influencing the nanoparticle size, morphology, stability, and functionality. It also addresses the challenges and considerations associated with each method, including the scalability, reproducibility, and biocompatibility. Future perspectives and emerging trends in PNPs’ production are discussed, emphasizing the potential for innovative strategies to overcome current limitations, which will propel the field forward for biomedical and therapeutic applications.
- 1 July 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (7) , 887
Open AccessAdvancing Tumor Therapy: Development and Utilization of Protein-Based Nanoparticles
Protein-based nanoparticles (PNPs) in tumor therapy hold immense potential, combining targeted delivery, minimal toxicity, and customizable properties, thus paving the way for innovative approaches to cancer treatment. Understanding the various methods available for their production is crucial for researchers and scientists aiming to harness these nanoparticles for diverse applications, including tumor therapy, drug delivery, imaging, and tissue engineering. This review delves into the existing techniques for producing PNPs and PNP/drug complexes, while also exploring alternative novel approaches. The methods outlined in this study were divided into three key categories based on their shared procedural steps: solubility change, solvent substitution, and thin flow methods. This classification simplifies the understanding of the underlying mechanisms by offering a clear framework, providing several advantages over other categorizations. The review discusses the principles underlying each method, highlighting the factors influencing the nanoparticle size, morphology, stability, and functionality. It also addresses the challenges and considerations associated with each method, including the scalability, reproducibility, and biocompatibility. Future perspectives and emerging trends in PNPs’ production are discussed, emphasizing the potential for innovative strategies to overcome current limitations, which will propel the field forward for biomedical and therapeutic applications.